Novel effects of recently introduced drugs for type 2 diabetes: using health data registers from Sweden, Denmark, and Norway to inform clinical care

The field of type 2 diabetes pharmacotherapy has been revolutionized by the introduction of SGLT2 inhibitors and GLP1 receptor agonists, which have remarkably favorable effects on cardiovascular events, heart failure, and renal outcomes. Data now indicate that there may be additional benefits with these drugs, beyond glycemic and cardiorenal effects.

Here, we will leverage our world-class expertise with rigorously designed real-world studies and use some of the most comprehensive health care data registers globally to address the following aims:The aim of work package 1 is to investigate if SGLT2 inhibitors are associated with reduced risk of atrial fibrillation; gout; serious liver events; and nephrolithiasis.The aim of work package 2 is to investigate if GLP1 receptor agonists are associated with reduced risk of serious liver events; Alzheimer’s disease; and Parkinson’s disease.Nationwide register data from clinical care in Sweden, Denmark, and Norway will be analyzed, utilizing a collaborative and data infrastructure that we have established.

The 3-year project applies state-of-the-art pharmacoepidemiology methods, including meticulous control for potential confounders.

Seeking to expand on our understanding of the full spectrum of effects of SGLT2 inhibitors and GLP1 receptor agonists, the results – which apply to disease prevention - are expected to inform clinical care and further inspire trials targeted at investigating treatment of established disease.